NOYES TIMOTHY P 4
4 · Aerovate Therapeutics, Inc. · Filed May 3, 2024
Insider Transaction Report
Form 4
NOYES TIMOTHY P
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-01$2.14/sh+10,000$21,400→ 10,000 total - Sale
Common Stock
2024-05-01$20.34/sh−9,035$183,793→ 965 total - Sale
Common Stock
2024-05-01$19.91/sh−1,357$27,018→ 0 total - Sale
Common Stock
2024-05-01$20.87/sh−965$20,135→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-01−10,000→ 353,381 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.855 to $20.85, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.855 to $20.89, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]Includes 1,357 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
- [F5]A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.